PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 231/56, A61K 31/415 — A1

(11) International Publication Number: **WO 99/23077**

(43) International Publication Date: 14 May 1999 (14.05.99)

(21) International Application Number: PCT/IB98/01710

(22) International Filing Date: 26 October 1998 (26.10.98)

(30) Priority Data:

60/064,229	4 November 1997 (04.11.97)	US
60/064,187	4 November 1997 (04.11.97)	US
60/064,024	4 November 1997 (04.11.97)	US
60/064,228	4 November 1997 (04.11.97)	US
60/064,198	4 November 1997 (04.11.97)	US

(71) Applicant *(for all designated States except US)*: PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: MARFAT, Anthony [US/US]; 333 Lantern Hill Road, Mystic, CT 06355 (US).


(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS

(57) Abstract


(I1)


(I2)

Therapeutically active compositions of matter and member species thereof are described which comprise indazole–containing compounds, said compounds and their therapeutic activity resulting directly from an indazole–for–catechol bioisostere replacement of a catechol–containing compound having the same therapeutic activity, where non–catechol substituents are the same or homologous before and after said replacement, and wherein said compositions of matter comprise a compound of Formula (I^1) or (I^2), or a pharmaceutically acceptable salt thereof, wherein in a preferred embodiment R^C is hydrogen; R^A is cyclohexyl; and R^B is ethyl. R_a and R_b are each individually and independently hydrogen or non–catechol substituents of said compounds resulting directly from an indazole–for–catechol bioisotere replacement of said catechol–containing compound having said therapeutic activity, where said non–catechol substituents are the same or homologous before and after said replacement, provided that both of R_a and R_b cannot be hydrogen at the same time. The therapeutic activity involved may comprise cholinesterase inhibitory activity, adrenergic α_1–antagonist and β_1–agonist activity, calcium channel inhibitory activity, antineoplastic activity, and phosphodiesterase type IV inhibitor activity.